We are live on ! Find out more
EUCRU

Eucrates Biomedical Acquisition Corp. Unit
EUCRU

Delisted

EUCRU was delisted on the 26th of April, 2023.

Back to rankings

17 hedge funds and large institutions have $16.1M invested in Eucrates Biomedical Acquisition Corp. Unit in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% less funds holding

Funds holding: 19 → 17 (-2)

13% less capital invested

Capital invested by funds: $18.4M → $16.1M (-$2.32M)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

86% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 7

Holders
17
Holders Change
-2
Holders Change %
-10.53%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$26.7K
2
TRCT
Tower Research Capital (TRC)
New York
+$993

Top Sellers

Rank Fund Capital Flow
1
SC
Sculptor Capital
New York
-$786K
2
PC
Periscope Capital
Ontario, Canada
-$780K
3
MF
Magnetar Financial
Illinois
-$576K
4
OMC
Old Mission Capital
Illinois
-$115K
5
WC
Wealthspring Capital
New York
-$82.4K

EUCRU Hedge Fund Activity: Q2 2022 in Review

17 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q2 2022, worth a combined $16.1M — down 13% from $18.4M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of EUCRU and 1 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 1 added.

The largest buyer was Glazer Capital LLC, adding an estimated $26.7K. The largest seller was Sculptor Capital, cutting an estimated $786K.

  • 17 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q2 2022, down from 19 in Q1 2022.
  • Funds reported $16.1M of Eucrates Biomedical Acquisition Corp. Unit stock for Q2 2022, down 13% quarter-over-quarter.
  • 1 fund opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q2 2022 and 3 closed out, a net change of -2 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Unit buyer in Q2 2022 was Glazer Capital LLC, an estimated $26.7K added.
  • The largest Eucrates Biomedical Acquisition Corp. Unit seller in Q2 2022 was Sculptor Capital, an estimated $786K sold.

Based on aggregated 13F filings for Q2 2022.